Nuvalent Inc. (NUVL), a clinical-stage biopharmaceutical company developing precisely targeted therapies for clinically proven kinase targets in cancer, will be presenting updated data from its ARROS-1 trial and ALKOVE-1 trial in the coming months.
ARROS-1 is a phase I/II clinical trial evaluating the company's lead drug candidate NVL-520 in patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors (ROS1-positive lung cancer develops when the ROS1 gene fuses with an adjacent gene. This type of lung cancer is typically aggressive and has the potential to metastasize to the brain and bones - Source: Lung Cancer Foundation of America).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.